Barclays raised the firm’s price target on Cigna (CI) to $385 from $382 and keeps an Overweight rating on the shares. Following Q1 earnings and “several negative data points” around Part D mix, Affordable Care Act trend, and preliminary 2026 ACA rates, the firm is more concerned on the Medicare Part D and individual ACA businesses, which it believes carry negative earnings risk for the balance of 2025 and face significant premium increases and disruption in 2026. With limited prospects of multiple expansion and an unfavorable managed care catalyst calendar, investors are likely to be more sensitive to earnings revisions, which skew negatively for Part D- and ACA-sensitive stocks, the analyst tells investors in a research note. Barclays continues to prefer hospitals to managed care.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CI:
- 3 Best Growth Stocks to Buy Now, 5/23/2025, According to Analysts
- Eli Lilly price target raised to $936 from $928 at Guggenheim
- Hims & Hers slides after Cigna unit launches obesity drug plan
- Trump Trade: Trump’s revised tax bill clears the House
- Evernorth weight loss drug price point attractive compared to Hims, says Truist